Pharma & Biotech Global Week in Review 27 June 2012 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

SD New York: Copaxone patents infringed, valid and enforceable: Teva v Sandoz et al (Beeser Ramamoorthy) (The IP Factor)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

HIV Medicines Alliance: If you can’t join ‘em, beat ‘em: new industry effort a jab at patent pool? (IP Watch)

BIO releases consultant report promoting IP rights (IP Watch) (IAM)

Australia: AUD $2 million Australia-WIPO MOU targets TIGAR, neglected diseases, developing IP systems and technology transfer (KEI)

Canada: Big pharma spending ratio on Canadian R&D continues to decline as IP demands increase (Michael Geist)

China’s new drug patent laws: A bitter pill for Big Pharma (IP Osgoode)

EU: Sumitomo CJEU reference: Can a supplementary protection certificate be issued when the application was made after expiry of an earlier marketing authorisation? (The SPC Blog)

EU: Daiichi in the CJEU: a note on the hearing (The SPC Blog)

EU: New Guidelines for Examination in the EPO follow Brustle v Greenpeace ruling on patenting stem cell inventions (IPKat)

India: Dealing with the cost of cancer treatment in India: Are patents the problem? (Spicy IP)

Mexico boosts data packaging exclusivity DPE protection (IP tango)

Netherlands: The Hague District Court: Reprise claims partial ownership of Ferring’s patent (EPLAW)

UK asks: should IPO Opinions service cover SPCs? (The SPC Blog)

US: The Myriad and ACLU supplemental briefs on remand to the Federal Circuit (Pharma Patents)

US: Non-legal perspectives on isolated DNA: The Watson and Holman amicus briefs in the Myriad remand (Pharma Patents)

US: What do the IP lawyers have to say in the Myriad remand? (Pharma Patents)

US: BIO 2012: Prometheus, Myriad, Classen, and the patentability of diagnostic methods (Patent Baristas)

US: BIO 2012: Everything America Invents Act (Patent Baristas)

US: Docs at BIO 2012: Session on prior user rights as a new IP option (Patent Docs)

US: Docs at BIO: Steve Burrill’s state of the biotech industry report 2012 (Patent Docs)

US: IP activity in the pharma and biotech space during 2012 (Intangitopia)

 

Products

Adderall (Dextroamphetamine) – US: FDA once again departs from conventional bioequivalence metrics and sets partial AUC parameters for generic Adderall XR (FDA Law Blog)

Baraclude (Entecavir) – US: Janssen files patent infringement suit against Teva in response to ANDA filing (Patent Docs)

Coenzyme Q10 – ALJ Rogers rules on motion for sanctions in Certain Coenzyme Q10 Products (337-TA-790) (ITC 337 Law Blog)

Combigan (Brimonidine, Timolol) – Canada: Federal Court grants prohibition order despite obviousness finding; cites uncertainty in comity law as basis: Allergan v Minister of Health and Apotex (Beeser Ramamoorthy)

Copaxone (Glatiramer acetate) – US: SD New York: Copaxone patents infringed, valid and enforceable: Teva v Sandoz et al (Beeser Ramamoorthy) (The IP Factor)

Evista (Raloxifene) – France: Tribunale de Grande Instance renders decision concerning grounds of invalidity of a drug patent: Teva v Eli Lilly (Kluwer Patent Blog)

Micardis HCT (Telmisartan, HCTZ) – France: Telmisartan combination – the Cour d’appel de Paris rules (The SPC Blog)

Micardis HCT (Telmisartan, HCTZ) – Spain: Pamplona Commercial Court revokes combination SPC: CINFA, Actavis v Boehringer Ingelheim (The SPC Blog)

Morphine sulphate – US: A 505(b)(2) NDA in search of a basis for submission and approval; the curious case of morphine sulfate oral solution (FDA Law Blog)

Nasonex (Mometasone hydrate) – US: New Jersey: Nasonex patent valid but not infringed: Schering v Apotex (Beeser Ramamoorthy)

Prezista (Darunvir) – US: Bristol-Myers Squibb files patent infringement suit against Sandoz in response to Para IV certification (Patent Docs)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: